Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers

PHASE3TerminatedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

June 30, 2017

Conditions
Chronic Diabetic Foot Ulcers
Interventions
BIOLOGICAL

CHAM

The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM

OTHER

Control

Standard of Care

Trial Locations (18)

11042

NSLIJHS, Lake Success

16602

University Orthopedics, Altoona

19107

Temple University, Philadelphia

20007

MedStar Georgetown University Hospital, Washington D.C.

27599

UNC, Chapel Hill

27710

Duke University, Durham

29303

Spartanburg Regional Healthcare System, Spartanburg

33169

Barry University Clinical Research, North Miami Beach

44195

Cleveland Clinic, Cleveland

75231

North Texas Podiatric Medicine and Surgery Associates, Dallas

77598

Texas Gulf Coast Medical Group, Webster

85723

SAVAHCS, Tucson

92009

ILD Research Center, Carlsbad

94115

Center for Clinical Research, San Francisco

94305

Stanford University, Stanford

94546

Center for Clinical Research, Castro Valley

02190

SSH, South Weymouth

08753

Ocean County Foot & Ankle Surgical Associates, Toms River

Sponsors
All Listed Sponsors
lead

Osiris Therapeutics

INDUSTRY